IPAROMLIMAB AND TUVONRALIMAB INJECTION
Clinical trials for IPAROMLIMAB AND TUVONRALIMAB INJECTION explained in plain language.
Never miss a new study
Get alerted when new IPAROMLIMAB AND TUVONRALIMAB INJECTION trials appear
Sign up with your email to follow new studies for IPAROMLIMAB AND TUVONRALIMAB INJECTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple threat: new combo aims to outsmart resistant colorectal cancer
Disease control Recruiting nowThis early-stage trial tests a combination of three treatments for people with advanced colorectal cancer who have already tried two standard therapies. The approach combines a special immune cell therapy (DC-CIK), an immunotherapy drug, and a targeted pill to attack the cancer f…
Matched conditions: IPAROMLIMAB AND TUVONRALIMAB INJECTION
Phase: EARLY_PHASE1 • Sponsor: JIANG LONGWEI • Aim: Disease control
Last updated May 17, 2026 03:12 UTC
-
New Triple-Threat attack on tough liver cancer
Disease control Recruiting nowThis study is testing a three-part treatment for advanced liver cancer that has spread into a major vein in the liver. The treatment combines immunotherapy (QL1706), a drug that blocks tumor blood supply (bevacizumab), and chemotherapy delivered directly into the liver's artery. …
Matched conditions: IPAROMLIMAB AND TUVONRALIMAB INJECTION
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC